LDS/Medical Tests/Alpha 1 Antitrypsin, Fecal

Alpha 1 Antitrypsin, Fecal

Alpha-1-Antitrypsin or Alpha-1-Antiprotease (α1AT) belong to the serpin superfamily of proteins with a broad spectrum of protease inhibition:

  • destructive neutrophil proteases including elastase, cathepsin G, proteinase 3
  • pancreatic elastase and trypsin, chymotrypsin
  • skin collagenases
  • synovial collagenases

The primary function of α1AT is inhibition of various proteolytic enzymes by forming firm but partially reversible complexes. α1AT is a 52-kDa glycoprotein, synthesized in the liver and to a lesser extent by macrophages and neutrophils. This results in protecting tissues from being harmed by enzymes released from cells when they are injured and inflamed. Alpha-1-Antitrypsin is produced by two copies of a protease inhibitor gene, also known as the SERPINA1 gene. This gene is co-dominant, which means that each SERPINA1 gene copy is responsible for producing half of the body’s Alpha-1-Antitrypsin. If there is a mutation in one or both of the gene copies, then less Alpha-1-Antitrypsin and/or dysfunctional protein is produced. If the production drops to or less than 30% of normal, the affected person will experience a disorder called Alpha-1-Antitrypsin deficiency.

Severe deficiency of Alpha-1-Antitrypsin results in an imbalance between proteinases and inhibitors within the lungs, and also in vascular manifestations, including cervical artery dissection and aneurysms. Without α1AT’s inhibitory effects, enzymes are free to break down elastin, which supports the elasticity of the lungs. This results in complications of the respiratory system including emphysema, chronic obstructive pulmonary disease in adults, and/or liver cirrhosis in adults or children. Therefore, decreased levels or deficiency of Alpha-1-Antitrypsin leads to excessive protease activity and panacinar emphysema in adults or liver disease in children. Cirrhosis of the liver and liver cancer in adults is also associated with abnormal phenotypes. Decreased levels of Alpha-1-Antitrypsin are also seen in chronic obstructive lung disease, chronic liver diseases, and liver cirrhosis that often leads to liver cancer.

Alpha-1-Antitrypsin is up-regulated during acute phase response to tissue necrosis and inflammatory conditions (acute phase reactant). Serum levels increase in rheumatoid arthritis, bacterial infections, vasculitis, carcinomatosis, and following estrogen level rises after puberty, during pregnancy or in conjunction with contraceptive medication use. Recent publications have also shown that even relatively minor changes, increase or decrease, in the level of Alpha-1-Antitrypsin as an acute phase protein are associated with the development of arterial hypertension and an increased risk of cardiovascular disease.

  • In diagnosis of early onset emphysema, especially when a person does not have obvious risk factors such as smoking or exposure to lung irritants (dust and fumes)
  • Alpha-1-antitrypsin is also ordered to help evaluate persistent jaundice and other signs of liver dysfunction
  • Aid in evaluation of neonatal hepatitis and cirrhosis
  • Used as an aid in evaluation of familial chronic obstructive lung disease
  • As an aid in evaluation of emphysema, cystic fibrosis and other lung fibrotic diseases

Increased in:

  • Inflammation, infection
  • Rheumatic disease
  • Malignancy
  • Liver cirrhosis
  • Chronic liver disease
  • Hepatocellular carcinoma
  • Pregnancy

Decreased in:

  • Congenital A1-Antitrypsin deficiency
  • Nephrotic syndrome
  • Some emphysema and other chronic obstructive lung disease (for more see Alpha-1-Antitrypsin phenotyping)

In the appropriate clinical setting, levels less than 125 mg/dL indicate the need for genotype testing. Levels Liver disease itself may cause low A1AT levels so that genotyping should be done to confirm suspected A1AT deficiency.

Also, A1AT is an acute phase protein so that patients who are acutely ill may have levels higher than would otherwise be the case.

Adult (M-phenotype): 78-200 mg/dL (0.78-2.00 g/L)

60 yrs: 115-200 mg/dL (1.15-2.00 g/L)

Nephelometry, radial immunodiffusion, molecular analysis by PCR and isoelectric focusing for phenotyping

Fresh stool collected in sterile container. 

Stability

  • Ambient: 1-3 days
  • Refrigerated: 7-14 days

 

Alpha-1-Antitrypsin phenotype or genotyping testing may be ordered if the Alpha-1-Antitrypsin concentration is lower than normal. DNA testing may be done as a follow-up to an alpha-1-antitrypsin level and phenotype. Once it has been established that an abnormality exists, then the DNA genetic testing can be ordered to establish which SERPINA1 gene alleles are present; Protein Electrophoresis, DNA sequencing, Liver Enzymes, Cystic Fibrosis Mutation.
Same day.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Thorax. 2000 Jul;55(7):614-8. [PMID: 10856323]
  • Respir Med. 2000 Aug;94 Suppl C:S1-2 [PMID: 10954246]
  • Mo Med. 2007 May-Jun;104(3):255-9. PMID: 17619502 ]
  • Curr Gastroenterol Rep. 2006 Feb;8(1):14-20. [PMID: 16510030]
  • Intern Med. 2004 Mar;43(3):223-6. [PMID: 15098605]
  • Semin Liver Dis. 1998;18(3):217-25. [PMID: 9773422]
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757.